• Innovative Eye Science

    Your vision is our focus

    Select Video
  • Play
    Select Video

At Inotek, we're working to define the future of glaucoma treatment.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.

A New Class of Glaucoma Therapy

Our most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind.

Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.

Read More >


Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

- Achieved Regulatory Designations for Fanconi Anemia (FA) in the U.S. and Europe; Registrational Trial on Track for 2019 - - Presented Promising Fanconi Anemia Data at ASGCT - - Adeno-associated Viral Vector Program Disclosure on Track for Fourth Quarter of 2018 - NEW YORK--(BUSINESS WIRE)--Aug. 8, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)...

Read More >